Sutro Biopharma Names Greg Chow As The New Chief Financial Officer

Sutro Biopharma, Inc., a company focused on developing site-specific and innovative antibody drug conjugates (ADCs) for cancer treatment, announced the appointment of Greg Chow as its new Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings more than 25 years of leadership experience in corporate finance, capital markets, investment banking, financial accounting, and drug development operations.

Before joining Sutro, Mr. Chow served as Chief Financial and Business Officer at NodThera, where he was instrumental in business development and financing efforts. He was previously the CFO at Freenome Holdings, supporting the successful completion of their Series F funding round. At Frontier Medicines, he also served as CFO, guiding the company through Series B and C financings and managing a major global collaboration with AbbVie. Earlier, as Executive Vice President and CFO at Aptose Biosciences, Mr. Chow led the company’s dual listing on Nasdaq and the Toronto Stock Exchange and helped raise over $225 million in capital.

Jane Chung, Chief Executive Officer of Sutro, stated, “We are delighted to welcome Greg to Sutro’s executive leadership team. Greg brings a strong track record of driving financial discipline, operational efficiency, and capital strategy across both private and public biotech companies. His leadership will be instrumental in ensuring we are well-positioned financially to achieve key clinical milestones across our wholly-owned pipeline of novel exatecan-based and dual-payload ADCs.”

Greg Chow, also added, “It’s an incredibly exciting time to join Sutro. The Company is uniquely positioned at the forefront of ADC innovation, with a robust pipeline, high value collaborations, and a powerful cell-free technology platform that enables precise, efficient drug discovery. As we continue to rapidly advance our novel ADCs and explore strategic growth opportunities, I look forward to helping drive Sutro’s financial strategy and operational excellence to support our mission of delivering next-generation therapies to patients in need.”

Mr. Chow began his career in investment banking, spending 14 years in senior roles at Wedbush Securities, RBC Capital Markets, and Wells Fargo Securities. He holds an MBA in Finance from the Wharton School at the University of Pennsylvania and a Bachelor’s degree in Business Economics from the University of California, Santa Barbara. Additionally, he is a Certified Public Accountant (inactive) in California.